DOI: 10.1055/s-00000088

TumorDiagnostik & Therapie

References

Hochhaus A, Saglio G, Hughes TP. et al.
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Leukemia 2016;
30: 1044-1054

Download Bibliographical Data

Access:
Access:
Access: